Dicerna Finds RNAi-Savvy Partner in Kyowa for Cancer Drug Program

Under the terms of the arrangement, Dicerna will receive from Kyowa $4 million up front and up to $120 million in research funding and milestones in exchange for the exclusive rights to an undisclosed cancer target. Additional targets may be added to the arrangement under similar terms.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.